Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday’s premarket session following positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis.
The stock’s surge comes as the company reported that 63.5% of participants achieved complete skin clearance.
Oruka Therapeutics (ORKA) Data Shows Strong Efficacy Across Key Endpoints
ORKA-001 demonstrated a favorable safety profile and sustained efficacy, with management planning to share longer-term data in the second half of 2026.
Other key secondary endpoints included PASI 90 at Week 16, achieved by 83% of participants, and IGA 0/1 at Week 16, achieved by 84% of participants.
One of 21 participants receiving a placebo reached PASI 100, IGA 0, PASI 90, and IGA 0/1 at Week 16, in line with historical psoriasis trials.
Cross-Trial Comparison Highlights Competitive Positioning
The company on Monday said that based on a cross-trial comparison, these data with ORKA-001 demonstrate numerically higher rates of skin clearance than all other IL-23p19 inhibitors and are comparable to the highest reported in plaque psoriasis for any mechanism of action.
Updated PK and PD data from the Phase 1 trial of ORKA-001 continue to support the potential for annual dosing.
Following a single 600 mg dose, ORKA-001 concentrations remained well above effective trough levels for an entire year, with sustained inhibition of IL-23 pathway signaling observed throughout that time period.
No impact of anti-drug antibodies on PK has been seen in either the Phase 1 or EVERLAST-A trials.
The chronic skin disease-focused company also continues to advance the Phase 2b EVERLAST-B trial, with data expected in 2027.
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $78.90. Recent analyst moves include:
- Wedbush: Outperform (Raises Target to $85.00) (April 15)
- Guggenheim: Buy (Maintains Target to $125.00) (April 13)
- BTIG: Buy (Raises Target to $78.00) (April 13)
ORKA Stock Price Activity: Oruka Therapeutics shares were up 39.07% at $96.00 during premarket trading on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments